Tenax Therapeutics Faces Securities Class Action Lawsuit
A law firm has filed a class action against Tenax Therapeutics over alleged investor losses, with a lead plaintiff deadline of December 28, 2026.
A New York-based law firm has announced a securities class action lawsuit against Tenax Therapeutics, Inc., targeting the Nasdaq-listed biopharmaceutical company over potential investor damages stemming from a nearly three-year period of alleged misconduct.
Bronstein Gewirtz & Grossman, LLC filed the suit on behalf of investors who purchased Tenax Therapeutics securities between November 13, 2023, and August 7, 2026. The firm is encouraging shareholders who suffered losses during that window to come forward and potentially participate in the litigation.
Read more InsCorp Posts 12% Revenue Gain in Q3, Sets Quarterly Dividend →
The lead plaintiff deadline is set for December 28, 2026, meaning eligible investors have a defined window to seek appointment as the primary representative in the case. Securities class actions typically allow individual investors to pool claims against a company when alleged misrepresentations or omissions are said to have artificially affected a stock's price.
Tenax Therapeutics trades on the Nasdaq exchange under the ticker symbol TENX. The lawsuit seeks to recover damages on behalf of the affected investor class, though the specific allegations underpinning the complaint were not fully detailed in the initial announcement. Investors are advised to consult legal counsel to assess their eligibility and potential recovery options before the court-imposed deadline.
Continue reading at All Financial Services & Investing
